{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T09:53:24Z","timestamp":1787478804308,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1245\/s10434-022-12238-0","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T14:03:15Z","timestamp":1660226595000},"page":"8037-8043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Omission of Intraoperative Frozen Section May Reduce Axillary Overtreatment Among Clinically Node-Negative Patients Having Upfront Mastectomy"],"prefix":"10.1245","volume":"29","author":[{"given":"Austin D.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif J.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"issue":"12","key":"12238_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310.","journal-title":"Lancet Oncol."},{"issue":"4","key":"12238_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","volume":"43","author":"\u00c1 S\u00e1volt","year":"2017","unstructured":"S\u00e1volt \u00c1, P\u00e9ley G, Polg\u00e1r C, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla\u2014surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672\u20139.","journal-title":"Eur J Surg Oncol."},{"issue":"13","key":"12238_CR3","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1245\/s10434-015-4528-x","volume":"22","author":"D Huo","year":"2015","unstructured":"Huo D, Hou N, Jaskowiak N, Winchester DJ, Winchester DP, Yao K. Use of postmastectomy radiotherapy and survival rates for breast cancer patients with T1\u2013T2 and one to three positive lymph nodes. Ann Surg Oncol. 2015;22(13):4295\u2013304.","journal-title":"Ann Surg Oncol."},{"issue":"9935","key":"12238_CR4","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"P McGale","year":"2014","unstructured":"McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127\u201335.","journal-title":"Lancet."},{"issue":"3","key":"12238_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/cncr.31080","volume":"124","author":"N Ohri","year":"2018","unstructured":"Ohri N, Sittig MP, Tsai CJ, et al. Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: a National Cancer Data Base analysis. Cancer. 2018;124(3):482\u201390.","journal-title":"Cancer."},{"issue":"9","key":"12238_CR6","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1245\/s10434-018-6519-1","volume":"25","author":"M Moossdorff","year":"2018","unstructured":"Moossdorff M, Nakhlis F, Hu J, et al. The potential impact of AMAROS on the management of the axilla in patients with clinical T1\u20132N0 breast cancer undergoing primary total mastectomy. Ann Surg Oncol. 2018;25(9):2612\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"12238_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-019-05243-7","volume":"176","author":"A Weiss","year":"2019","unstructured":"Weiss A, Lin H, Babiera GV, et al. Evolution in practice patterns of axillary management following mastectomy in patients with 1\u20132 positive sentinel nodes. Breast Cancer Res Treat. 2019;176(2):435\u201344.","journal-title":"Breast Cancer Res Treat."},{"key":"12238_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.radonc.2018.07.006","volume":"131","author":"ML Gregorowitsch","year":"2019","unstructured":"Gregorowitsch ML, Verkooijen HM, Houweling A, et al. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients. Radiother Oncol. 2019;131:221\u20138.","journal-title":"Radiother Oncol."},{"issue":"2","key":"12238_CR9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1245\/s10434-021-10726-3","volume":"29","author":"O Kantor","year":"2022","unstructured":"Kantor O, Means J, Grossmith S, et al. Optimizing axillary management in clinical T1\u20132N0 mastectomy patients with positive sentinel lymph nodes. Ann Surg Oncol. 2022;29(2):972\u201380.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"12238_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10549-019-05520-5","volume":"180","author":"AB Tadros","year":"2020","unstructured":"Tadros AB, Moo TA, Stempel M, Zabor EC, Khan AJ, Morrow M. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy. Breast Cancer Res Treat. 2020;180(1):197\u2013205.","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"12238_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clbc.2013.04.004","volume":"13","author":"A S\u00e1volt","year":"2013","unstructured":"S\u00e1volt A, Polg\u00e1r C, Musonda P, et al. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients? Clin Breast Cancer. 2013;13(5):364\u201370.","journal-title":"Clin Breast Cancer."},{"issue":"36","key":"12238_CR12","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2016.69.1188","volume":"34","author":"A Recht","year":"2016","unstructured":"Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol. 2016;34(36):4431\u201342.","journal-title":"J Clin Oncol."},{"key":"12238_CR13","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology Version 2.2022: Breast Cancer. Available at: www.nccn.com. Accessed 1 April 2022."},{"issue":"2","key":"12238_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/jnci\/djx148","volume":"110","author":"R Jagsi","year":"2018","unstructured":"Jagsi R, Momoh AO, Qi J, et al. Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction. J Natl Cancer Inst. 2018;110(2):157\u201365.","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"12238_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1245\/s10434-012-2689-4","volume":"20","author":"C Shah","year":"2013","unstructured":"Shah C, Kundu N, Arthur D, Vicini F. Radiation therapy following postmastectomy reconstruction: a systematic review. Ann Surg Oncol. 2013;20(4):1313\u201322.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"12238_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","volume":"17","author":"J de Boniface","year":"2017","unstructured":"de Boniface J, Frisell J, Andersson Y, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17(1):379.","journal-title":"BMC Cancer."},{"key":"12238_CR17","doi-asserted-by":"crossref","unstructured":"Goyal A, Mann B, Thompson AM. POSNOC: positive sentinel node\u2014adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy. Meeting Abstract No. TPS600, 2018 American Society of Clinical Oncology Annual Meeting. J Clin Oncol. 2018;36(15):TPS600.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS600"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12238-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T20:06:04Z","timestamp":1667851564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12238-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":17,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["12238"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12238-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Monica Morrow has received honoraria from Exact Sciences and Roche. Dr. Atif J. Khan has received honoraria from Exact Sciences, and owns stock in Novavax and Xtrava. All other authors have no conflict of interest disclosures to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}